Switch to LPV/r monotherapy

Pilot LPV/r M03-613 LPV/r Mono KalMo OK OK04 KALESOLO MOST HIV-NAT 077

50 HIV-1 infected Thaï children failing first line NRTIs + NNRTI, switched to double ritonavir-boosted PIs for 144 weeks (LPV/r + SQV = 90%) ; 40 children with virological suppression (HIV-1 RNA < 50 c/mL at least 3 months apart) switched to LPV/r 230/57.5 mg/m2 bid monotherapy

Female: 50%, Median age: 11.7 years

At W48 – HIV-1 RNA < 50 c/mL: 72.5%– Still on LPV/r monotherapy, N = 31 (78%)– Returned to double boosted PIs due to failure, N = 9– No emergence of major protease resistance mutations

Conclusion – Simplifying second-line treatment from double-boosted PI therapy to

LPV/r monotherapy allows for sustain virologic suppression in the majority of children after 48 weeks of follow-up

Bunupuradah T, AIDS 2011;25:315-23

HIV-NAT 077 Study: Switch double PI/r to LPV/r monotherapy

HIV-NAT 077HIV-NAT 077